Heska (HSKA) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of Heska (NASDAQ:HSKA) from a sell rating to a hold rating in a research note published on Thursday morning.

Several other equities analysts have also commented on the company. Zacks Investment Research raised Heska from a strong sell rating to a hold rating in a research report on Wednesday, July 18th. ValuEngine lowered Heska from a buy rating to a hold rating in a research report on Monday, July 30th. Benchmark initiated coverage on Heska in a research report on Thursday, July 19th. They set a buy rating and a $120.00 price target on the stock. Finally, TheStreet lowered Heska from a b rating to a c+ rating in a research report on Monday, August 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $107.50.

Shares of NASDAQ HSKA traded up $2.05 during midday trading on Thursday, hitting $102.14. The stock had a trading volume of 685 shares, compared to its average volume of 47,930. The firm has a market capitalization of $758.25 million, a P/E ratio of 48.35 and a beta of 0.50. Heska has a 1-year low of $56.59 and a 1-year high of $114.50.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, August 7th. The medical research company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.07. The business had revenue of $29.66 million for the quarter, compared to analyst estimates of $30.19 million. Heska had a return on equity of 11.49% and a net margin of 4.67%. On average, equities analysts expect that Heska will post 1.67 earnings per share for the current fiscal year.

In other Heska news, COO Jason A. Napolitano sold 2,500 shares of Heska stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $113.50, for a total transaction of $283,750.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Steven M. Eyl sold 1,051 shares of Heska stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $98.00, for a total value of $102,998.00. Following the sale, the executive vice president now owns 15,401 shares in the company, valued at $1,509,298. The disclosure for this sale can be found here. Insiders have sold a total of 57,828 shares of company stock worth $5,854,060 over the last three months. 14.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of HSKA. Schwab Charles Investment Management Inc. increased its holdings in Heska by 2.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 34,394 shares of the medical research company’s stock worth $2,720,000 after purchasing an additional 892 shares during the last quarter. Northern Trust Corp increased its holdings in Heska by 4.6% during the 1st quarter. Northern Trust Corp now owns 122,827 shares of the medical research company’s stock worth $9,712,000 after purchasing an additional 5,451 shares during the last quarter. BlackRock Inc. increased its holdings in Heska by 5.5% during the 1st quarter. BlackRock Inc. now owns 928,761 shares of the medical research company’s stock worth $73,437,000 after purchasing an additional 48,347 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Heska by 4.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 191,044 shares of the medical research company’s stock valued at $15,106,000 after acquiring an additional 8,513 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Heska by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 49,975 shares of the medical research company’s stock valued at $3,952,000 after acquiring an additional 1,162 shares during the last quarter. Institutional investors own 88.94% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Featured Story: How are the companies in the S&P 500 selected?

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply